BioLife Solutions (NASDAQ: BLFS) reported Q3 EPS of ($0.23), $0.07 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $40.7 million versus the consensus estimate of $42.02 million.

GUIDANCE:

BioLife Solutions sees FY2022 revenue of $160-164 million, versus the consensus of $163.4 million.

For earnings history and earnings-related data on BioLife Solutions (BLFS) click here.